577778-40-6

Basic information

• Product Name: 4-Piperidinamine,1-(1-oxopropyl)-(9CI)
• Synonyms: 4-Piperidinamine,1-(1-oxopropyl)-(9CI);1-propionyl-4-piperidinamine(SALTDATA: HCl);1-(1-Oxopropyl)-4-piperidinamine HCl;1-Propanone, 1-(4-amino-1-piperidinyl)-
• CAS NO: 577778-40-6
• Molecular Formula: C₈H₁₆N₂O
• Molecular Weight: 156.227
• Product Categories: AMINETERTIARY
• Mol File: 577778-40-6.mol

Chemical Properties

• Boiling Point: 288.3±33.0 °C(Predicted)
• Appearance: /
• Density: 1.022±0.06 g/cm3(Predicted)
• PKA: 9.79±0.20(Predicted)
• CAS DataBase Reference: 4-Piperidinamine,1-(1-oxopropyl)-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Piperidinamine,1-(1-oxopropyl)-(9CI)(577778-40-6)
• EPA Substance Registry System: 4-Piperidinamine,1-(1-oxopropyl)-(9CI)(577778-40-6)

Safety Data

• Hazardous Substances Data: 577778-40-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Piperidinamine,1-(1-oxopropyl)-(9CI) is used as an intermediate in the synthesis of various pharmaceuticals and organic compounds. Its unique chemical structure and properties make it a valuable component in the development of new drugs and medications.
Used in Organic Synthesis:
In the field of organic synthesis, 4-Piperidinamine,1-(1-oxopropyl)-(9CI) serves as a key building block for the creation of a wide range of organic compounds. Its reactivity and versatility allow chemists to incorporate it into various molecular structures, enabling the synthesis of complex organic molecules with specific properties and applications.

Upstream product

• 73874-95-0 (piperidin-4-yl)carbamic acid tert-butyl ester 
• 13035-19-3 4-aminopiperidine 
• 79-03-8 propionyl chloride 
• 1029643-92-2 N-phenylmethylidenepiperidinyl-4-amine 
• 91623-91-5 1-propionyl-4-piperidone 
• 41979-39-9 4-piperidone hydrochloride 
• 577778-37-1 1-(4-benzylamino-piperidin-1-yl)-propan-1-one 

Downstream Products

• 1246188-43-1 1-(2-fluorophenyl)-3-(1-propionylpiperidin-4-yl)urea 
• 1246188-52-2 1-(4-perfluoroisopropylphenyl)-3-(1-propionylpiperidin-4-yl)urea 
• 1246188-53-3 1-(2-methyl-4-perfluoroisopropylphenyl)-3-(1-propionylpiperidin-4-yl)urea 
• 1246188-45-3 1-(2-chlorophenyl)-3-(1-propionylpiperidin-4-yl)urea 
• 1246188-34-0 1-(4-nitrophenyl)-3-(1-propionylpiperidin-4-yl)urea 
• 1373817-96-9 1-(4-benzyloxyphenyl)-3-(1-propionylpiperidin-4-yl)urea 
• 1246188-21-5 1-phenyl-3-(1-propionylpiperidin-4-yl)urea 
• 1246188-23-7 1-(1-propionylpiperidin-4-yl)-3-(pyridin-3-yl)urea 
• 1246188-40-8 1-(4-bromophenyl)-3-(1-propionylpiperidin-4-yl)urea 
• 1246188-48-6 1-(2,6-dichlorophenyl)-3-(1-propionylpiperidin-4-yl)urea 
• 1246188-44-2 1-(3-chlorophenyl)-3-(1-propionylpiperidin-4-yl)urea 
• 1246188-42-0 1-(3-fluorophenyl)-3-(1-propionylpiperidin-4-yl)urea 
• 1246188-35-1 methyl 4-(3-(1-propionylpiperidin-4-yl)ureido)benzoate 
• 1246188-50-0 1-(1-propionylpiperidin-4-yl)-3-(4-(trifluoromethyl)phenyl)urea 

Relevant articles and documents

Synthesis and Structure–Activity Relationship Studies of Benzimidazole-4,7-dione-Based P2X3 Receptor Antagonists as Novel Anti-Nociceptive Agents

P2X3 receptors (P2X3R) are ATP-gated ion channels predominantly expressed in C-and Aδ-fiber primary afferent neurons and have been introduced as a novel therapeutic target for neurological disorders, including neuropathic pain and chronic cough. Because of its localized distribution, antagonism of P2X3R has been thoroughly considered, and the avoidance of issues related to CNS side effects has been proven in clinical trials. In this article, benzimidazole-4,7-dione-based derivatives were introduced as a new chemical entity for the development of P2X3R antagonists. Starting from the discovery of a hit compound from the screening of 8364 random library compounds in the Korea Chemical Bank, which had an IC50 value of 1030 nM, studies of structure–activity and structure–property relationships enabled further optimization toward improving the antagonistic activities as well as the drug’s physicochemical properties, including metabolic stability. As for the results, the final optimized compound 14h was developed with an IC50 value of 375 nM at P2X3R with more than 23-fold selectivity versus P2X2/3R, along with properties of metabolic stability and improved solubility. In neuropathic pain animal models evoked by either nerve ligation or chemotherapeutics in male Sprague-Dawley rats, compound 14h showed anti-nociceptive effects through an increase in the mechanical withdrawal threshold as measured by von Frey filament following intravenous administration.

POLYCYCLIC COMPOUNDS SOLUBLE EPOXIDE HYDROLASE INHIBITORS

The present invention relates to soluble epoxide hydrolase (sEH) inhibitors of formula (I) to processes for their obtention and to their therapeutic indications.

Acyl piperidine inhibitors of soluble epoxide hydrolase

Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases.

1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: Structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain

1,3-Disubstituted ureas possessing a piperidyl moiety have been synthesized to investigate their structure-activity relationships as inhibitors of the human and murine soluble epoxide hydrolase (sEH). Oral administration of 13 1-aryl-3-(1-acylpiperidin-4-yl)urea inhibitors in mice revealed substantial improvements in pharmacokinetic parameters over previously reported 1-adamantylurea based inhibitors. For example, 1-(1-(cyclopropanecarbonyl) piperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea (52) showed a 7-fold increase in potency, a 65-fold increase in Cmax, and a 3300-fold increase in AUC over its adamantane analogue 1-(1-adamantyl)-3-(1-propionylpiperidin-4-yl) urea (2). This novel sEH inhibitor showed a 1000-fold increase in potency when compared to morphine by reducing hyperalgesia as measured by mechanical withdrawal threshold using the in vivo carrageenan induced inflammatory pain model.

4-Aminopiperidine derivatives as a new class of potent cognition enhancing drugs

Extrusion of one of the nitrogens of the piperazine ring of potent nootropic drugs previously described gave 4-aminopiperidine analogues that maintained high cognition enhancing activity in the mouse passive avoidance test. One of the new compounds (9, active at 0.01 mg/kg ip) may represent a new lead for the development of cognition enhancers useful to treat the cognitive deficit produced by neurodegenerative pathologies like Alzheimer's disease.